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Abstract
Objectives. To determine maternal-fetal transplacental passage of meropenem in the ex vivo human perfusion model.
Study design. Term placentae (n=6) were collected immediately after delivery. A single cotyledon was localized, perfused
and stabilized with physiologic Eagles minimal essential medium containing 3% bovine albumin and heparin as described by
Chalier (Chalier JC. Criteria for evaluating perfusion experiments and presentation results. Contrib Gynecol Obstet 1985;
13:32–39). Meropenem was added to the maternal medium in concentrations similar to maternal serum peak and trough
levels, then perfused through the maternal circulation of the cotyledon. To assess transfer and accumulation, ﬂuid aliquots
from both the maternal and fetal compartments were collected over an hour at deﬁned intervals in an open and closed
system. Antipyrine
14C was added to the medium in order to calculate the transport fraction and clearance indexes.
Meropenem and antipyrine
14C concentrations were determined by High-pressure Liquid Chromatography and liquid
scintillation, respectively.
Results. Mean antipyrine transport fraction was 2.33 + 0.25. Maternal and fetal mean meropenem peak concentrations
were 54.3 + 3.3 mg/ml and 2.2 + 0.18 mg/ml, respectively. Whereas, maternal and fetal mean trough concentrations were
12.7 + 1.3 mg/ml and 0.41+ 0.10 mg/ml, respectively. Mean peak clearance index was 0.077 + 0.007 and the mean trough
was 0.052 + 0.015. Mean accumulation for the peak and trough concentrations of meropenem were 0.9 and 2.95 mg/ml,
respectively.
Conclusions. Transplacental passage of meropenem was incomplete in the ex vivo human placental perfusion model.
Accumulation was also noted in the fetal compartment
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Condensation
Incomplete transplacental passage and accumulation
of meropenem were noted in the ex vivo human
placental perfusion model.
Introduction
Meropenem is a synthetic carbapenem b–lactam
antibiotic with a broad antimicrobial activity against
gram-negative, gram-positive and anaerobic micro-
organisms.It is as effective as imipenem/cilastatin and
is more effective than cephalosporin-based combina-
tion in the treatment of a range of serious infections.
Resistance to meropenem is uncommon [1–3].
Use of this particular antibiotic is increasing
secondary to microbial resistance to other antibio-
tics. In addition, meropenem has been administered
to pregnant women. Like many other medications,
information regarding pharmacokinetics is limited
for meropenem in pregnancy [4,5]. Our study
objective was to quantify the maternal to fetal
transplacental passage of meropenem in the ex vivo
human placental perfusion model.
Material and methods
Term placentae were collected immediately after
delivery from either cesarean sections or vaginal
deliveries in accordance with the University of Texas
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Board for Human Studies’ guidelines and were
transported to the laboratory in normal saline
immediately after delivery.
The single cotyledon placental perfusion system
was used as described by Chalier [6]. A fetal artery
and vein on the chorionic plate was cannulated with
3.0F and 5.0F catheters, respectively (Figure 1). The
fetal circulation of the selected cotyledon was gently
perfused with Eagles minimal essential media plus
3% bovine albumin and 1.0 units/ml of heparin
(Sigma Chemical Co., St. Louis, MO).
The localized cotyledon and surrounding placental
tissue were transferred to a temperature-controlled
chamber (378C) where the fetal circulation was
perfused in a closed-system at a rate between 4.5
and 5 mL/min for 20 minutes to remove any residual
blood and to stabilize the perfusion pressure between
35 and 45 mmHg (Figure 2). Prior to perfusing, two
18-guage needles were inserted into the intervillous
space of the cotyledon to reestablish the maternal
circulation (Figure 3). Maternal ﬂow rate was
17 mL/min. Those placental cotyledons, which failed
to reach a stable baseline pressure or found to have a
vascular leak, were discarded.
The maternal and fetal compartments consisted of
150 mL of Eagle’s minimal essential medium (pH 7.2
– 7.4), which were aerated with 95% oxygen and 5%
carbon dioxide and were continually mixed by a
magnetic stirring bar. Transfer studies were per-
formed with meropenem (Zeneca Pharmaceuticals,
Wilmington, DE). Meropenem was added to the
maternal medium in concentrations similar to serum
peak and trough levels. Experiments were ﬁrst
conducted in an open-open system to determine
transport fraction, then in a closed-closed re-
circulation system to determine accumulation. The
clearance index of meropenem was also calculated.
Fluid aliquots from both the maternal and fetal
compartments were collected for analysis.
A total of 6 placentae met criteria to be included in
the study. A trough transfer study for meropenem
was performed in one placenta and a peak study in
another. Both, peak and trough transfer studies were
conducted in the remaining four. Studies were
completed ﬁrst in an open system for 1 hour and
then in a closed system. For example, in the 4
placentae, trough studies were performed in an open
system and then in a closed system, followed by peak
studies in an open system and then in a closed one.
Lastly, transport fraction and clearance indexes
were determined for each placenta by means of the
14C antipyrine reference method of Challier [6].
Placentae were studied in a nonrecirculating (open)
system for 60 minutes to determine transport
fraction of
14C antipyrine. Greater than 40%
maternal-fetal transfer of antipyrine is an indication
of a successful maternal-fetal match.
Meropenem and antipyrine
14C concentrations
were measured by High-pressure Liquid Chromato-
graphy (HPLC) and liquid scintillation, respectively.
Reproducibility studies on the meropenem assay
were performed.
The HPLC analysis of meropenem was carried out
on all Waters Associate instruments (Medford, MA).
The meropenem standards were prepared from
laboratory assay powder provided by Zeneca Phar-
maceuticals. The HPLC assay of meropenem
consisted of preparation of a standard curve to
breach the therapeutic range of the drug. All speci-
mens and standards were extracted in aliquots of
0.5 mL. To each tube was added 2.5 mL of aceto-
nitrile to precipitate blood, serum and other proteins.
All samples were centrifuged at 8006g for 10
minutes and the supernatant was decanted into a
clean 10 mm x 100 mm screw-capped test tube. Five
milliliters of methylene chloride was then added to
each tube. The tubes were mixed on a vortex mixer
and were again centrifuged at 8006g. The upper
aqueous layer was removed and placed in HPLC
micro tubes and placed in a Waters 717 +
autosampler. An injection of 20 mL was made.
The HPLC mobile phase consisted of 95% mmole
ammonium acetate and 5% acetonitrile (pH 4.0).
Figure 1. Fetal circulation. (a) Cannulization of vein. (b) Establishing fetal circulation.
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C18 with a ﬂow rate of 1.5 mL/min. The HPLC pump
was a Waters model 510. The Waters 481 detector
settings were a wavelength of 298 mmw i t ha
sensitivity setting of 0.01–0.05 absorbance units.
The retention time was about 7 minutes and the peak
height was recorded on a Kipp and Zonan (Holland)
10 mV recorder. Using least squares regression
analysis and the correlation coefﬁcient of the
standard curve all specimens were quantiﬁed and
reported. Reproducibility studies were done on
meropenem over a 3 day period to determine the
within batch and between batch reproducibility.
Results
For the HPLC determination of meropenem con-
centrations, reproducibility studies provided values
with a minimum sensitivity of 0.2 mg/mL; and, a
within batch and between batch reproducibility of
490%. Maternal and fetal Meropenem concentra-
tions for the maternal and fetal perfusate are listed in
Table I. For the maternal perfusate, the mean peak
and trough levels and standard error were 54.3 mg/
mL+3.3 and 12.7+1.3 mg/mL, respectively and
for the fetal, they were 2.2+1.8 mg/mL and 0.44+
0.10 mg/mL. The clearance index and accumulation
for both peak and trough levels are shown in Table




The pharmacokinetics and pharmacodynamics of
meropenem have been described in patients who are
healthy or critically ill, who have renal or hepatic
Figure 2. Placental perfusion model.
Figure 3. Maternal circulation. (a) Perfused cotyledon. (b) 18 gauge probes for maternal perfusate.
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However, little is known regarding its pharmacoki-
netics and safety in the mother and the fetus during
pregnancy [4,5]. Meropenem is listed as Category B
in pregnancy [5]. In other words, no adequate or
well-controlled studies have been carried out in
pregnant women. No fetal harm was noted in rats
and cynomolgus monkeys at doses of 1.8 and 3.7
times the human dose [5]. One abstract was available
that described the efﬁcacy and safety of meropenem
during pregnancy (n=13) and during the puerperal
period (n=11) [9]. Our study provides initial data
regarding transplacental passage of meropenem in
the ex vivo human model.
Meropenem is similar in structure to imipenem,
another carbapenem beta-lactam antibiotic. Imipe-
nem’s pharmacokinetics is known to change during
pregnancy [8]. When compared to healthy, non-
pregnant women, Imipenem’s volume of distribution
was larger, clearance was accelerated and peak levels
were signiﬁcantly lower in those who were pregnant
[8]. Meropenem mean values for peak plasma
concentrations and volume of distribution after 1 g
doses are known for a healthy individual and are 54.8
to 61.6 mg/mL and 12.5 to 23 L, respectively [3].
These values during pregnancy are unknown.
Heikkila ¨ and co-workers demonstrated transpla-
cental passage of imipenem and noted therapeutic
concentrations in the fetal compartments late in
pregnancy [8]. In our study, transplacental passage
of meropenem was noted to occur in the ex vivo
model. However, concentrations of meropenem in
the fetal efﬂuence were less than maternal levels and
were below therapeutic levels. Therefore, placental
transfer was incomplete. The low clearance index
obtained in this study might be explained by the
solubility and molecular weight of meropenem. Most
drugs cross the placenta by simple diffusion. Rate of
diffusion is dependent upon solubility, molecular
weight and concentration of the free drug. Hydro-
philic substances cross the placenta slower than
lipophilic ones. Meropenem is hydrophilic with a
molecular weight of 437.52 d [3]. Further research is
needed in vivo to determine both fetal and maternal
concentrations of meropenem.
Normal physiologic changes of pregnancy may
alter the pharmacokinetics of meropenem not
apparent in our ex vivo model. In pregnancy, blood
volume and glomerular ﬁltration rate increase 40–
50%. Because meropenem and its inactive metabo-
lite are excreted by the kidney through glomerular
ﬁltration and tubular secretion serum concentrations
may be decreased in pregnancy [3,8].
Accumulation of meropenem in the fetal compart-
ment was noted in the closed system. Minimal
accumulation was noted at a maternal peak and
trough concentrations. Fetal accumulation increased
with maternal meropenem concentrations but re-
mained below the therapeutic levels.
Our study suggests that meropenem crosses the
placenta incompletely with lower fetal concentrations
than maternal. In addition, the placental clearance
and fetal accumulation of meropenem are low at
both peak and trough levels. Further investigation of
Table I. Meropenem concentrations.
Peak Concentration (mg/mL) Trough Concentration(mg/mL)
Placenta # Maternal Fetal Maternal Fetal
1 63.7 1.97 17.1 0.68
2 53.3 2.80 12.1 0.57
3 — — 13.0 0.5
4 59.8 1.80 12.3 0.36
5 45.8 2.45 9.1 0.10
6 49.0 2.17 — —
Table II. Meropenem clearance index and accumulation.
Clearance Index Accumulation (mg/mL)
Placenta # Peak Trough Peak Trough
1 0.062 0.078 3.3 1.0
2 0.062 0.067 3.5 1.4
3 — 0.011 — 1.5
4 0.085 0.082 5.9 0.7
5 0.096 0.020 2.8 0.7
6 0.082 — 5.4 —
226 M. Hnat & R. E. Bawdonmeropenem in vivo is needed to determine both the
maternal and fetal pharmacokinetics.
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